Kuelbs Family Office Invests in Biotech Company Elevian, Supporting $40 Million Funding Round

Share Article

“We are pleased to have the Kuelbs family as investors in Elevian and John as a business advisor,” said Dr. Mark Allen, Co-Founder and CEO of Elevian. “His insight and experience building valuable companies across numerous industries provide a valuable perspective to the company.”

Texas-based investor John A. Kuelbs announces his commitment to transformative health initiatives with his investment in Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases.

“Over the past century in America, the average life expectancy has increased from 50 years to 80 years. Given the ever-increasing progress of scientific understanding, I think it’s quite possible to achieve a lifespan of 100 reasonably healthy years,” said Kuelbs. “Elevian is one of the top companies working to enhance longevity, with impressive preclinical data demonstrating the ability to therapeutically repair damaged tissues and organs.”

The Series A funding round will enable Elevian to submit an investigational new drug application, scale manufacturing and complete Phase 1 clinical trials for its lead indication of stroke recovery – the first of many potential applications for its breakthrough drug candidate.
“We are pleased to have the Kuelbs family as investors in Elevian and John as a business advisor,” said Dr. Mark Allen, Co-Founder and CEO of Elevian. “His insight and experience building valuable companies across numerous industries provide a valuable perspective to the company.”

About Elevian
Elevian is an emerging biotech company developing medicines that restore youthful regenerative capacity, with the potential to treat and prevent multiple age-related diseases. Elevian's scientific founders, working at the Harvard Department of Stem Cell and Regenerative Biology, discovered that treatment with the circulating factor GDF11 can regenerate the heart, brain, muscle and other tissues. Elevian has acquired exclusive, worldwide rights to Harvard's patent portfolio concerning GDF11. The company is developing new medicines that target the GDF11 pathway. Elevian's lead drug candidate (recombinant human GDF11) has demonstrated efficacy in preclinical models of stroke, obesity, Type 2 diabetes, heart failure, Alzheimer's disease, and many other age-related diseases. The company has also established additional programs focused on the discovery and development of novel proteins, antibodies and small molecule drugs that target the GDF11 pathway. For more information, please visit http://www.elevian.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nick Kuelbs